Versage E - Search Results

1

Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.

Okkerse P, Hay JL, Versage E, Tang Y, Galluppi G, Ravina B, Verma A, Williams L, Aycardi E, Groeneveld GJ. Okkerse P, et al. Among authors: versage e. Br J Clin Pharmacol. 2016 Jul;82(1):108-17. doi: 10.1111/bcp.12941. Epub 2016 May 13. Br J Clin Pharmacol. 2016. PMID: 27016000 Free PMC article. Clinical Trial.

2

First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica.

Rolan PE, O'Neill G, Versage E, Rana J, Tang Y, Galluppi G, Aycardi E. Rolan PE, et al. Among authors: versage e. PLoS One. 2015 May 11;10(5):e0125034. doi: 10.1371/journal.pone.0125034. eCollection 2015. PLoS One. 2015. PMID: 25962165 Free PMC article. Clinical Trial.

3

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, Steinman L, Medori R. Bushnell SE, et al. Among authors: versage em. Neurology. 2012 Aug 7;79(6):531-7. doi: 10.1212/WNL.0b013e318259e123. Epub 2012 May 9. Neurology. 2012. PMID: 22573631 Free PMC article.

4

Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects.

Peterson J, Van Twuijver E, Versage E, Hohenboken M. Peterson J, et al. Among authors: versage e. Vaccines (Basel). 2022 Mar 23;10(4):497. doi: 10.3390/vaccines10040497. Vaccines (Basel). 2022. PMID: 35455245 Free PMC article.

5

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults.

Versage E, van Twuijver E, Jansen W, Theeuwes A, Sawlwin D, Hohenboken M. Versage E, et al. Vaccines (Basel). 2021 Dec 11;9(12):1468. doi: 10.3390/vaccines9121468. Vaccines (Basel). 2021. PMID: 34960214 Free PMC article.

6

Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.

Chanthavanich P, Versage E, Van Twuijver E, Hohenboken M. Chanthavanich P, et al. Among authors: versage e. Vaccine. 2021 Nov 16;39(47):6930-6935. doi: 10.1016/j.vaccine.2021.10.010. Epub 2021 Oct 25. Vaccine. 2021. PMID: 34711436 Free article. Clinical Trial.

7

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States.

Boikos C, McGovern I, Ortiz JR, Puig-Barberà J, Versage E, Haag M. Boikos C, et al. Among authors: versage e. Vaccines (Basel). 2022 Sep 2;10(9):1456. doi: 10.3390/vaccines10091456. Vaccines (Basel). 2022. PMID: 36146534 Free PMC article. Review.

8

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions.

Jelinek T, Schwarz TF, Reisinger E, Malfertheiner P, Versage E, Van Twuijver E, Hohenboken M. Jelinek T, et al. Among authors: versage e. Vaccines (Basel). 2024 Apr 30;12(5):481. doi: 10.3390/vaccines12050481. Vaccines (Basel). 2024. PMID: 38793732 Free PMC article.

9

Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture-derived H5N1 (aH5n1c) influenza vaccine in adults and older adults.

Frey SS, Versage E, Van Twuijver E, Hohenboken M. Frey SS, et al. Among authors: versage e. Hum Vaccin Immunother. 2023 Dec 31;19(1):2193119. doi: 10.1080/21645515.2023.2193119. Epub 2023 Apr 14. Hum Vaccin Immunother. 2023. PMID: 37057755 Free PMC article.

10

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.

Poder A, Oberije J, Meyer J, Heymer P, Molrine D, Versage E, Isakov L, Zhang Q, Hohenboken M. Poder A, et al. Among authors: versage e. Vaccines (Basel). 2023 Sep 26;11(10):1528. doi: 10.3390/vaccines11101528. Vaccines (Basel). 2023. PMID: 37896932 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters